Cargando…

Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone

Purpose. 5-Fluorouracil (5-FU) has shown radiosensitizing properties in vitro. This paper reports the effects of radiotherapy and concomitant intravenous 5-FU radiosensitization in the treatment of advanced bone sarcomas. Subjects/methods. Four patients with large inoperable bone sarcomas (three cho...

Descripción completa

Detalles Bibliográficos
Autores principales: Zambatis, Charalambos, Skarlatos, John, Koukourakis, Michael, Kosma, Lambrini, Giatromanolaki, Alexandra, Beroukas, Kostantinos, Yannakakis, Dimitrios
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 1998
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395373/
https://www.ncbi.nlm.nih.gov/pubmed/18521229
http://dx.doi.org/10.1080/13577149878127
_version_ 1782155491160358912
author Zambatis, Charalambos
Skarlatos, John
Koukourakis, Michael
Kosma, Lambrini
Giatromanolaki, Alexandra
Beroukas, Kostantinos
Yannakakis, Dimitrios
author_facet Zambatis, Charalambos
Skarlatos, John
Koukourakis, Michael
Kosma, Lambrini
Giatromanolaki, Alexandra
Beroukas, Kostantinos
Yannakakis, Dimitrios
author_sort Zambatis, Charalambos
collection PubMed
description Purpose. 5-Fluorouracil (5-FU) has shown radiosensitizing properties in vitro. This paper reports the effects of radiotherapy and concomitant intravenous 5-FU radiosensitization in the treatment of advanced bone sarcomas. Subjects/methods. Four patients with large inoperable bone sarcomas (three chondrosarcomas and one fibrosarcoma) were treated with hypofractionated radiotherapy and concomitant 5-FU bolus injection (300 mg m(−2)) before each fraction of radiotherapy. A radiation fraction of 5 Gy was given twice a week to a normalized total dose (α/β=4 Gy) of 75 Gy. Results. The regimen was well tolerated, the main toxicity being grade I/II diarrhoea in two cases with pelvic irradiation. Treatment interruption for 1 week was necessary in two cases with pelvic disease but not in two patients treated for sarcoma of the extremities. A complete symptomatic relief was obtained in all cases immediately after the third to the fifth fraction and the median duration was 10 months. Computed tomography scan documented a partial response in 2/4 cases. Discussion. Hypofractionated radiotherapy combined with potential lethal damage inhibitors for bone sarcomas requires further investigation.
format Text
id pubmed-2395373
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-23953732008-06-02 Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone Zambatis, Charalambos Skarlatos, John Koukourakis, Michael Kosma, Lambrini Giatromanolaki, Alexandra Beroukas, Kostantinos Yannakakis, Dimitrios Sarcoma Research Article Purpose. 5-Fluorouracil (5-FU) has shown radiosensitizing properties in vitro. This paper reports the effects of radiotherapy and concomitant intravenous 5-FU radiosensitization in the treatment of advanced bone sarcomas. Subjects/methods. Four patients with large inoperable bone sarcomas (three chondrosarcomas and one fibrosarcoma) were treated with hypofractionated radiotherapy and concomitant 5-FU bolus injection (300 mg m(−2)) before each fraction of radiotherapy. A radiation fraction of 5 Gy was given twice a week to a normalized total dose (α/β=4 Gy) of 75 Gy. Results. The regimen was well tolerated, the main toxicity being grade I/II diarrhoea in two cases with pelvic irradiation. Treatment interruption for 1 week was necessary in two cases with pelvic disease but not in two patients treated for sarcoma of the extremities. A complete symptomatic relief was obtained in all cases immediately after the third to the fifth fraction and the median duration was 10 months. Computed tomography scan documented a partial response in 2/4 cases. Discussion. Hypofractionated radiotherapy combined with potential lethal damage inhibitors for bone sarcomas requires further investigation. Hindawi Publishing Corporation 1998-03 /pmc/articles/PMC2395373/ /pubmed/18521229 http://dx.doi.org/10.1080/13577149878127 Text en Copyright © 1998 Hindawi Publishing Corporation. http://creativecommons.org/licenses/by/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zambatis, Charalambos
Skarlatos, John
Koukourakis, Michael
Kosma, Lambrini
Giatromanolaki, Alexandra
Beroukas, Kostantinos
Yannakakis, Dimitrios
Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone
title Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone
title_full Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone
title_fullStr Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone
title_full_unstemmed Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone
title_short Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone
title_sort concurrent hypofractionated radiotherapy and 5-fluorouracil for advanced sarcomas of the bone
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395373/
https://www.ncbi.nlm.nih.gov/pubmed/18521229
http://dx.doi.org/10.1080/13577149878127
work_keys_str_mv AT zambatischaralambos concurrenthypofractionatedradiotherapyand5fluorouracilforadvancedsarcomasofthebone
AT skarlatosjohn concurrenthypofractionatedradiotherapyand5fluorouracilforadvancedsarcomasofthebone
AT koukourakismichael concurrenthypofractionatedradiotherapyand5fluorouracilforadvancedsarcomasofthebone
AT kosmalambrini concurrenthypofractionatedradiotherapyand5fluorouracilforadvancedsarcomasofthebone
AT giatromanolakialexandra concurrenthypofractionatedradiotherapyand5fluorouracilforadvancedsarcomasofthebone
AT beroukaskostantinos concurrenthypofractionatedradiotherapyand5fluorouracilforadvancedsarcomasofthebone
AT yannakakisdimitrios concurrenthypofractionatedradiotherapyand5fluorouracilforadvancedsarcomasofthebone